Trial Profile
A study to evaluate ipragliflozin as an initial therapy for type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Alogliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jul 2015 New trial record
- 09 Jun 2015 Results (n=51) assessing effect of ipagliflozin on lipotoxicity and Beta Cell Functionpresented at the 75th Annual Scientific Sessions of the American Diabetes Association.